Report details drugs behind Crohn's disease market's projected rise to $12.6bn
The Crohn’s disease (CD) market is expected to grow from $7.4 billion in 2019 to $12.6 billion by 2029 across the eight major markets at a compound annual growth rate (CAGR) of 5.5%, according to GlobalData.
The company’s report, Crohn’s Disease – Global Drug Forecast and Market Analysis to 2029, states that growth will be driven by the launch of new drugs, most of which are expected to debut between 2023 and 2025, that will target the moderate-to-severe patient population, as well as the often-neglected CD patient with fistulizing disease.
Need for new MOAs
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze